Clinical Trial Search

Primary: Comparison of the Mean Day 5 CD34+Cells/kg Yield Between the Two Arms — 11.6; 10.0 cells/kg

Primary: Best Overall Response (BOR) in Participants With T790M Mutation — 0; 1; 7; 6 Participants

Primary: Percentage of Participants With Incidence of Grade II-IV GVHD — 33; 31; 21 Percentage of participants

Primary: Occurrence of Grade 3 or Higher Adverse Events (AEs) — 18; 24; 20; 28 Participants

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe…

Primary: Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate) — 4; 0; 3; 1 participants

Primary: Number of Participants Who Could Tolerate Twice Daily Oxytocin — 13; 11 Participants

Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants

Primary: Number of Participants With Best Clinical Response (Core) — 0 Participants

Primary: Percent Change in Mean Arterial Pressure (MAP) — 26.7; 30.8; 26.5; 24.5 % change

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died — 0; 0; 1; 1 participants

Primary: Participants Who Had Undetectable HIV-1 RNA Levels at Less Than 400 Copies/mL at Six Month — 45; 16 Participants — p=0.431

Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01

Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants

Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…